Stock price performance
搜索文档
Here's What Key Metrics Tell Us About GoodRx (GDRX) Q3 Earnings
ZACKS· 2025-11-05 09:31
GoodRx Holdings, Inc. (GDRX) reported $196.03 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 0.4%. EPS of $0.08 for the same period compares to $0.08 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $193.43 million, representing a surprise of +1.34%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they comp ...
Here's What Key Metrics Tell Us About Intapp (INTA) Q1 Earnings
ZACKS· 2025-11-05 09:01
For the quarter ended September 2025, Intapp (INTA) reported revenue of $139.03 million, up 17% over the same period last year. EPS came in at $0.24, compared to $0.21 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $135.48 million, representing a surprise of +2.62%. The company delivered an EPS surprise of +26.32%, with the consensus EPS estimate being $0.19.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...
Kratos (KTOS) Reports Q3 Earnings: What Key Metrics Have to Say
ZACKS· 2025-11-05 08:01
Kratos (KTOS) reported $347.6 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 26%. EPS of $0.14 for the same period compares to $0.11 a year ago.The reported revenue represents a surprise of +7.12% over the Zacks Consensus Estimate of $324.5 million. With the consensus EPS estimate being $0.12, the EPS surprise was +16.67%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...
Here's What Key Metrics Tell Us About Advanced Micro (AMD) Q3 Earnings
ZACKS· 2025-11-05 08:01
For the quarter ended September 2025, Advanced Micro Devices (AMD) reported revenue of $9.25 billion, up 35.6% over the same period last year. EPS came in at $1.20, compared to $0.92 in the year-ago quarter.The reported revenue represents a surprise of +6% over the Zacks Consensus Estimate of $8.72 billion. With the consensus EPS estimate being $1.17, the EPS surprise was +2.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...
FS KKR Capital (FSK) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
ZACKS· 2025-10-31 23:38
核心财务表现 - 预计季度每股收益为0.57美元,较去年同期下降23% [1] - 预计季度营收为3.7607亿美元,较去年同期下降14.7% [1] 分析师预期调整 - 过去30天内,季度每股收益共识预期被上调0.4% [2] - 盈利预期的调整趋势与股票短期价格表现存在强相关性 [3] 关键投资收入指标预测 - 预计“投资收入-费用收入”为982万美元,同比下降53.2% [5] - 预计“投资收入-股息及其他收入”为7461万美元,同比增长16.6% [5] - 预计“投资收入-实物支付利息收入”为4979万美元,同比下降24.6% [5] - 预计“投资收入-利息收入”为2.3933亿美元,同比下降17.5% [6] 近期市场表现 - 过去一个月公司股价回报率为-1.6%,同期标普500指数上涨2.1% [6] - 公司目前Zacks评级为4级(卖出)[6]
Compared to Estimates, Bandwidth (BAND) Q3 Earnings: A Look at Key Metrics
ZACKS· 2025-10-31 00:30
财务业绩总览 - 2025年第三季度营收为1.919亿美元,同比下降1% [1] - 季度每股收益为0.36美元,低于去年同期的0.43美元 [1] - 营收超出市场一致预期1.05%,但每股收益低于预期5.26% [1] 关键运营指标 - 净留存率为105%,低于分析师平均预估的110.6% [4] - 国际地区营收为2615万美元,同比增长10.8%,并高于分析师预估的2460万美元 [4] - 北美地区营收为1.6574亿美元,同比下降2.7%,与分析师预估的1.6577亿美元基本持平 [4] 业务线收入 - 消息附加费收入为5009万美元,高于三位分析师的平均预估4704万美元 [4] - 云通信收入为1.4181亿美元,低于三位分析师的平均预估1.4327亿美元 [4] 股价表现 - 公司股价在过去一个月上涨4.9%,表现优于同期上涨3.6%的标普500指数 [3]
Unlocking Q3 Potential of Diamondback (FANG): Exploring Wall Street Estimates for Key Metrics
ZACKS· 2025-10-30 22:17
核心业绩预期 - 华尔街分析师预计公司季度每股收益为285美元,同比下降157% [1] - 预计季度总收入为346亿美元,同比增长309% [1] - 过去30天内,市场对季度每股收益的共识预期下调了71% [2] 收入细分预期 - 石油、天然气及天然气液体总收入预计达327亿美元,同比增长388% [5] - 其中石油销售收入预计为278亿美元,同比增长288% [5] - 天然气液体销售收入预计为35264亿美元,同比增长671% [6] 产量与运营指标预期 - 平均日产量预计为920,999桶油当量/天,远超去年同期的571,098桶油当量/天 [6] - 总生产量(综合)预计达85,050千桶油当量,较去年同期的52,541千桶有显著增长 [11] - 石油总产量预计为45,917千桶,高于去年同期的29,537千桶 [10] - 天然气液体总产量预计为20,222千桶,较去年同期的11,918千桶大幅提升 [8] - 天然气总产量预计为113,46590亿立方英尺,高于去年同期的66,51900亿立方英尺 [9] 价格预期 - 经对冲的石油平均价格预计为63美元/桶,低于去年同期的72美元/桶 [7] - 石油平均价格预计为63美元/桶,低于去年同期的73美元/桶 [11] - 经对冲的天然气液体平均价格预计为18美元/桶,与去年同期持平 [7] - 天然气液体平均价格预计为17美元/桶,略低于去年同期的18美元/桶 [8] 市场表现与展望 - 公司股价在过去一个月内上涨01%,同期标普500指数上涨36% [12] - 公司Zacks评级为4级(卖出),预计近期表现将弱于整体市场 [12]
Ahead of Exelon (EXC) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
ZACKS· 2025-10-30 22:16
核心财务预测 - 华尔街分析师预测公司季度每股收益为0.76美元,同比增长7% [1] - 预计季度营收将达到63.5亿美元,同比增长3.2% [1] - 在过去30天内,市场对季度每股收益的共识预期下调了7.2% [2] 关键业务指标预测 - 预计PECO运营收入为11.2亿美元,同比增长8.5% [5] - 预计ComEd运营收入为22.3亿美元,同比增长0.2% [5] - 预计PHI运营收入为18.5亿美元,同比下降0.8% [5] - 预计BGE运营收入为11.4亿美元,同比增长9.2% [6] 电力业务收入细分 - 预计ComEd电力收入为22.3亿美元,同比增长0.2% [6] - 预计ACE电力收入为4.9093亿美元,同比下降9.1% [6] - 预计PHI电力收入为18亿美元,同比下降2.2% [7] - 预计DPL电力收入为4.4627亿美元,同比增长1.7% [7] - 预计BGE电力收入为9.5亿美元,同比增长2.7% [8] 天然气业务收入细分 - 预计PHI天然气收入为3676万美元,同比增长59.8% [7] - 预计BGE天然气收入为2.0876亿美元,同比增长100.7% [8] - 预计PECO天然气收入为1.3512亿美元,同比增长93% [8] 近期市场表现 - 公司股价在过去一个月上涨4.8%,同期标普500指数上涨3.6% [9] - 公司Zacks评级为3级(持有),预计短期内表现将与整体市场同步 [9]
Wall Street's Insights Into Key Metrics Ahead of Suncor Energy (SU) Q3 Earnings
ZACKS· 2025-10-30 22:16
核心财务预测 - 华尔街分析师预测公司季度每股收益为0.85美元,较去年同期下降21.3% [1] - 预计季度营收为82.8亿美元,较去年同期下降13.5% [1] - 在过去30天内,市场对季度每股收益的共识预期上调了19.1% [2] 运营指标预测 - 预计每日总精炼产品销量为58.845万桶石油,低于去年同期的61.23万桶 [5] - 预计油砂业务每日总销售量为79.104万桶石油,高于去年同期的76.45万桶 [5] - 预计北美东部地区每日原油加工量为22.422万桶,低于去年同期的23.54万桶 [6] - 预计北美西部地区每日原油加工量为23.424万桶,低于去年同期的25.22万桶 [6] - 预计每日总原油加工量为45.846万桶,低于去年同期的48.76万桶 [7] 生产量预测 - 预计油砂业务中未升级沥青的日产量为30.612万桶,显著高于去年同期的26.22万桶 [7] - 预计油砂业务中已升级产品的日产量为48.492万桶,低于去年同期的51.38万桶 [8] - 预计油砂业务中已升级产品的日销售量为48.492万桶,低于去年同期的51.03万桶 [8] - 预计油砂业务中未升级沥青的日销售量为30.612万桶,高于去年同期的25.42万桶 [9] - 预计Fort Hills项目总沥青日产量为18.43万桶,高于去年同期的16.6万桶 [10] - 预计Syncrude项目总日产量为18.092万桶,低于去年同期的21.38万桶 [11] - 预计加拿大勘探与生产业务日产量为5.152万桶,略低于去年同期的5.26万桶 [11]
Guardant Health (GH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-10-30 08:31
财务业绩摘要 - 公司2025年第三季度营收为2.652亿美元,同比增长38.5% [1] - 季度每股收益为-0.39美元,较去年同期-0.45美元有所改善 [1] - 营收超出Zacks一致预期2.3458亿美元,带来13.05%的正面意外 [1] - 每股收益超出Zacks一致预期-0.48美元,带来18.75%的正面意外 [1] 运营指标表现 - 肿瘤检测总量为74,000次,高于三位分析师平均估计的66,824次 [4] - 肿瘤业务收入为1.844亿美元,高于四位分析师平均估计的1.6462亿美元 [4] - 生物制药和数据业务收入为5473万美元,高于四位分析师平均估计的4838万美元 [4] - 筛查业务收入为2411万美元,高于四位分析师平均估计的1631万美元 [4] - 许可及其他业务收入为195万美元,略低于三位分析师平均估计的235万美元 [4] 市场表现与展望 - 公司股价在过去一个月上涨11.4%,表现优于Zacks S&P 500综合指数3.8%的涨幅 [3] - 公司目前Zacks评级为3(持有),预示其近期表现可能与整体市场同步 [3] - 关键运营指标的表现优于分析师预期,为评估公司财务健康状况提供了更准确的图景 [2]